Clinical Endocrinology · 1986 · 118 citations · 11 references
MedicinePharmacokineticsPharmacologyBioavailabilityBone MetabolismBone ScintigraphyBone HealthDrug AbsorptionFood Effect On AbsorptionFood Effects On AbsorptionOral Absorption AssessmentSubjectsTc-99m Methylene Diphosphonate Imaging
Absorption of the diphosphonate etidronate (HEDP) was measured in 20 volunteer subjects at two centres (Glasgow and Madison) using a new method based on simultaneous administration of HEDP and intravenous 99mTc-HEDP (Osteoscan). The mean absorption of HEDP in fasting subjects in Glasgow was 3.5% (range 1-8.9%) and in Madison 1.5% (0.7-2.8%) (P less than 0.035). In four subjects studies were repeated with good agreement between results (mean 3.9 cf. 3.5%). Six subjects had studies repeated when drug was ingested with food and in all cases absorption was effectively reduced to zero. We conclude that absorption of HEDP is significantly higher in normal subjects in Glasgow than in Madison. This may be of importance with regard to the finding of histological osteomalacia and fracture associated with HEDP use in Glasgow.
11
FOCAL OSTEOMALACIA DUE TO LOW-DOSE DIPHOSPHONATE THERAPY IN PAGET'S DISEASE
B.F. Boyce, I. Fogelman, Stuart H. Ralston et al. · The Lancet · 1984 · 198 citations
The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease.
Ignac Fogelman, R. G. Bessent, John G. Turner et al. · PubMed · 1978 · 192 citations
DIPHOSPHONATES IN PAGET'S DISEASE
R.G.G. Russell, C. Preston, Roger Smith et al. · The Lancet · 1974 · 179 citations
Medicine, Dermatology, Neurology +3
Diphosphonate Therapy of Paget's Disease of Bone
R E Canfield, William Rosner, Jonathan B. Skinner et al. · The Journal of Clinical Endocrinology & Metabolism · 1977 · 163 citations